CSIMarket Company Name, Ticker, Industry, else..
 
Pacific Biosciences Of California Inc   (NASDAQ: PACB)
 
Price: $1.3500 $0.05 3.846%
Day's High: $1.350000023841858 Week Perf: -0.74 %
Day's Low: $ 1.29 30 Day Perf: 15.38 %
Volume (M): 2,754,339 52 Wk High: $ 2.73
Volume (M$): $ 0 52 Wk Avg: $1.63
Open: $1.29 52 Wk Low: $1.07



 Market Capitalization (Millions $) 413
 Shares Outstanding (Millions) 306
 Employees 485
 Revenues (TTM) (Millions $) 160
 Net Income (TTM) (Millions $) -129
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 10

Business Description


Pacific Biosciences of California Inc.
(also known as PacBio) is an American biotechnology company founded in 2004 by Stephen Turner and Jonas Korlach.
The company is headquartered in Menlo Park, California, and specializes in advanced DNA sequencing technology.
PacBio aims to revolutionize the field of genomics and personalize medicine through its innovative sequencing technology.
The company's flagship product is the PacBio Sequel System, which is a high-throughput DNA sequencing instrument that uses Single Molecule, Real-Time (SMRT) technology.
This technology allows for the real-time observation of DNA replication, leading to highly accurate and long-read sequencing results.
The system can detect various types of genomic variations, including non-coding DNA, structural variations, and epigenetic modifications.
PacBio's sequencing technology has numerous applications, including studies of genetic diseases, cancer research, microbiome analysis, and forensic analysis.
The company has collaborations with major academic institutions and research centers worldwide, such as the Wellcome Trust Sanger Institute, the Broad Institute, and the Max Planck Institute.
In 2020, PacBio merged with a special purpose acquisition company (SPAC) called Schr'dinger to go public.
The combined company trades on the Nasdaq under a new ticker symbol, "PACB.
" In summary, Pacific Biosciences Of California Inc is a biotech firm known for inventing and producing advanced DNA sequencing technology that allows for highly accurate and long-read sequencing results used for study of genetic diseases, cancer research, microbiome analysis and forensic analysis.
The company has collaborations with major academic institutions worldwide and went public in 2020 in collaboration with Schr'dinger through SPAC.


   Company Address: 1305 O’Brien Drive Menlo Park 94025 CA
   Company Phone Number: 521-8000   Stock Exchange / Ticker: NASDAQ PACB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
A   -1.94%    
AVTR        2.67% 
BIO   -0.49%    
ILMN        1.22% 
RVTY        1.1% 
TXG        1.8% 
• View Complete Report
   



Clinical Study

Unraveling Genomic Complexity HiFi Genomes Bridge Research and Clinical Applications

Published Thu, Nov 6 2025 8:40 AM UTC

The landscape of genomic research is evolving rapidly, particularly with regard to the need for precision and accuracy in identifying clinically relevant genetic variants. A recent multi-center study has demonstrated the capabilities of Pacific Biosciences’ (PacBio) HiFi genome sequencing technology, establishing its potential value in both research and clinical applicati...
Partnership

A Milestone in Genomic Medicine PacBio and Berry Genomics Pioneer Long-Read Sequencing in China

Published Tue, Nov 4 2025 10:05 PM UTC

In a transformative stride toward advancing genomic medicine, PacBio has partnered with Berry Genomics to secure the first regulatory approval for clinical long-read sequencing in China. The National Medical Products Administration (NMPA) has officially granted approval for the Sequel II CNDx system, a revolutionary platform that leverages PacBio s High-Fidelity (HiFi) seque...
Partnership

Unraveling the Epigenetic Code PacBio and EpiCypher Pioneering a New Era in Genetic Research

Published Wed, Sep 3 2025 1:25 PM UTC

In an era where the intricacies of genetics unravel myriad pathways leading to our understanding of health and disease, Pacific Biosciences of California Inc. (PacBio) has forged a strategic partnership with EpiCypher, a leap that promises to illuminate the shadows in epigenomics. This collaboration, featuring the Fiber-seq workflow, represents a significant advancement for ...
Product Service News

Advancing Genomic Horizons PacBios Innovations in Long-Read Sequencing

Published Thu, Nov 7 2024 3:35 AM UTC

In a significant stride towards democratizing genomic research, Pacific Biosciences (PacBio) has launched the Vega System, a new benchtop sequencing platform priced at $169,000. This development aims to make highly accurate long-read sequencing accessible to a wider array of laboratories. The Vega System utilizes HiFi sequencing technology, known for its precision, which is ...
Partnership

PacBio and Singapores National Precision Medicine Program Forge Pioneering Collaboration to Elevate Cancer G...

Published Fri, Oct 11 2024 1:05 PM UTC

In a groundbreaking alliance poised to redefine the landscape of cancer genomics, PacBio has joined forces with Singapore’s National Precision Medicine (NPM) program. This strategic partnership aims to harness the full potential of PacBio’s state-of-the-art HiFi sequencing technology, a sophisticated solution designed to deliver unparalleled insights into genetic diversi...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.58
Price to Sales (Expected) -
Price to Book 174.5
PEG (TTM) -

Financial Strength Current
Quick Ratio 4.22
Working Capital Ratio 5.65
Leverage Ratio (MRQ) 329.67
Total Debt to Equity 272.23
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.43 $
Revenues (TTM) 0.52 $
Cash Flow (TTM) -
Cash 0.9 $
Book Value 0.01 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 329,880
Net Income per Employee (TTM) -265,105
Receivable Turnover Ratio (TTM) 5.01
Inventory Turnover Ratio (TTM) 1.93
Asset Turnover Ratio (TTM) 0.2

Profitability Ratios Current
Gross Margin (MRQ) 34.86 %
Operating Margin (MRQ) -22.68 %
Net Margin (MRQ) -22.46 %
Net Cash Flow Margin (MRQ) -20.07 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Pacific Biosciences Of California Inc's Segments
Reportable Segment    100.91 % of total Revenue
Americas    45.29 % of total Revenue
Europe Middle East and Africa    29.23 % of total Revenue
Asia-Pacific    26.39 % of total Revenue
Product revenue    85.59 % of total Revenue
Instrument revenue    26.39 % of total Revenue
Consumable revenue    59.21 % of total Revenue
Service and other revenue    15.32 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.